RxDoctor Payments Data

Mohamed Salem, MD

Interventional Cardiology · Bethlehem, PANPI 1366517336

Payments from drug & device makers

$4,255in general payments, 2019–2025

Across 31 payments — averaging $137.24 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Hikma Pharmaceuticals USA$3K
  • Medtronic$312
  • Rapid Medical Ltd$150
  • Abiomed$137
  • AstraZeneca$125
  • E.r. Squibb & Sons, L.L.C.$116
  • plus $415 from 6 others

What the payments were for

  • Consulting fees$2,00047%
  • Speaking & faculty fees$1,00024%
  • Food & beverage$1,25529%

General payments by program year

21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,255 in reported general payments places this provider in the 30th percentile of 281 interventional cardiology providers in Pennsylvania.

See all interventional cardiology providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$142,252
Medicare patients
417
Services billed
1,253

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban145$173,874
EntrestoSacubitril/Valsartan17$17,228
XareltoRivaroxaban16$15,985
Repatha SureclickEvolocumab14$12,624
Metoprolol Succinate137$2,340
Pitavastatin Calcium14$1,600
Ezetimibe69$1,500
ClopidogrelClopidogrel Bisulfate101$1,028
Rosuvastatin Calcium64$995
Diltiazem 24hr Er (Cd)Diltiazem Hcl24$898
Torsemide29$801
Amlodipine Besylate90$696
Atorvastatin Calcium72$633
Isosorbide Mononitrate ErIsosorbide Mononitrate36$602
Hydralazine Hcl31$574

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$93$17,22817 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 30th percentile of 281 interventional cardiology providers in Pennsylvania.

Other interventional cardiology in Bethlehem

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →